Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)

Abstract Background The pro-inflammatory cytokines interleukin (IL)-4 and IL-13 and their cognate receptor IL-4 receptor-alpha are key targets for asthma therapy. Elarekibep is an inhaled Anticalin protein developed to inhibit IL-4 receptor-alpha signalling in patients with moderate-to-severe asthma...

Descrición completa

Detalles Bibliográficos

Principais autores:	Tania Hugo, Andrew R Harper, Jacob Leander, Philip Gardiner, Robert Palmér, Pål Lundin, David Bock, Xiao-Hong Zhou, Irina Bondarenko, Steve Burns, Erol Wiegert, Mary F Fitzgerald, David R Close, David J Keeling, Hitesh Pandya, Maria G Belvisi, Paul M O’Byrne
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2026-04-01
Series:	Respiratory Research
Assuntos:	moderate-to-severe asthma inhaled biologics IL-4Rα
Acceso en liña:	https://doi.org/10.1186/s12931-026-03613-6
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!